Cytokinetics EVP Sells 15,000 Shares at $60.28, Slashes Stake to 50,440
Cytokinetics Executive Vice President Andrew Callos sold 15,000 shares at $60.28 on January 5, reducing his holdings to 50,440 shares. Callos also sold 1,042 shares at $65.96 on December 8 and 52,486 shares at $65.95 on December 5, totaling roughly $3.46 million according to SEC filings.
1. Executive Vice President Executes Significant Stock Sales
On January 5, 2026, Cytokinetics Executive Vice President Andrew Callos disclosed the sale of 15,000 shares of company stock, reducing his total holdings to 50,440 shares. This transaction followed two previous dispositions in December: 1,042 shares on December 8 and 52,486 shares on December 5. Collectively, Callos’s December trades generated approximately $3.46 million in proceeds. All transactions were reported through timely SEC filings, providing transparency for investors tracking insider sentiment.
2. Market Capitalization and Trading Activity Reflect Biotech Volatility
Cytokinetics maintains a market capitalization near $7.3 billion, with average daily volumes exceeding two million shares in recent weeks. Over the past year, the stock has traded between a low of $29.31 and a high of $70.98, illustrating investor response to pipeline developments and industry headwinds. Trading volumes on announcement days—such as the recent insider sale disclosures—have spiked by as much as 35%, underscoring the market’s sensitivity to executive-level transactions.
3. J.P. Morgan Healthcare Conference Presentation Scheduled
President and CEO Robert I. Blum is slated to deliver a presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM Pacific Time. The live webcast will be accessible via the company’s Investors & Media website, with the replay archived for 90 days. Management is expected to outline upcoming catalysts, including pivotal trial readouts and regulatory milestones in major markets.
4. Advancing a Diversified Cardiac Muscle Biology Pipeline
Cytokinetics continues to build on over 25 years of muscle biology research, with MYQORZO™ (aficamten) already approved for symptomatic obstructive hypertrophic cardiomyopathy by the U.S. FDA and China’s NMPA. A positive opinion from the European Medicines Agency’s CHMP paves the way for a first-quarter 2026 decision on EU marketing authorization. Additionally, the company is investigating aficamten in non-obstructive HCM, developing omecamtiv mecarbil for heart failure with reduced ejection fraction, and evaluating ulacamten for heart failure with preserved ejection fraction, all supported by ongoing preclinical programs.